Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amphastar Pharmaceuticals Inc (AMPH) vs Oracle Corporation (ORCL) Price & Performance

Amphastar Pharmaceuticals IncTrade
Oracle CorporationTrade

Price performance (Past 24H)

Key statistics

Amphastar Pharmaceuticals Inc vs Oracle Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Oracle Corporation trades at $146.72 (market cap $423.49B). The key difference: Oracle Corporation is far larger — about 490.2× Amphastar Pharmaceuticals Inc's market cap, and Oracle Corporation pays a 1.36% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

AMPHORCL
Market Cap
$863.95M$423.49B
Sector
HealthTechnology
52-Week High
$30.81$328.33
52-Week Low
$16.87$114.99
Enterprise Value
$1.26B$552.74B
Dividend Yield
1.36%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amphastar Pharmaceuticals Inc

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

Oracle Corporation

Oracle Corporation (ORCL) trades at $146.94, up 2.45% today, showing strong momentum with three consecutive earnings beats. The stock demonstrates robust fundamentals with revenue growth from $57.4B in 2025 to $67.4B projected for 2026, net margins expanding to 25.37%, and impressive ROE of 58.56%. Technical indicators show bullish momentum with the current price above key support levels, while analyst consensus remains strongly positive with a $253.63 price target representing significant upside potential.

Oracle presents a compelling growth story driven by AI infrastructure expansion and cloud services adoption. The company's transformation into an AI infrastructure leader offers substantial upside, though risks include high valuation multiples (P/E 25.22, P/S 6.36) and significant capital expenditure requirements for AI investments that could pressure near-term cash flow. The upcoming Q2 2026 earnings report on June 10 will be critical for validating growth trajectory.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amphastar Pharmaceuticals Inc

Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.

Read more on AMPH

About Oracle Corporation

Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.

Read more on ORCL